Anti-Rheumatics Market Trend to Reflect Tremendous Growth Potential With A Highest CAGR by 2031

PORTLAND, KS, UNITED STATES, February 13, 2025 /EINPresswire.com/ -- Rheumatoid arthritis is an autoimmune disorder, which causes painful and swollen joints in patients. The treatment of this medical condition involves the use of various drugs, known as anti-rheumatics. For instance, different type of drugs involved in the treatment of rheumatoid arthritis include disease modifying anti-rheumatic drugs (DMARD's), nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, and others. These drugs have different mechanism of action on the medical condition. For instance, DMARDs modify the course of the action and NSAIDs act on the symptoms of the disease such as pain. Furthermore, these drugs are available on prescription and also over-the-counter.

According to the report, the global anti-rheumatics industry accounted for $57.22 billion in 2018, and is estimated to reach $71.93 billion by 2026, growing at a CAGR of 2.9% from 2019 to 2026.

Increase in incidence of rheumatoid arthritis, surge in geriatric population, and rise in incidence of obesity across the world drive the growth of the global anti-rheumatics market. However, side effects related to the medication and higher cost of biologics & biosimilars hinder the growth of the market. On the other hand, R&D activities in the field of biosimilars and novel biologics present numerous opportunities in the market.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/6289

Rise in prevalence of rheumatoid arthritis, increase in elderly population, and surge in incidence of obesity worldwide fuel the growth of the global anti-rheumatics market. On the other hand, side effects related to the medication and higher cost of biologics & biosimilars curtail down the growth to certain extent. However, R&D activities in the field of biosimilars and novel biologics are expected to pave the way for multiple opportunities in the industry.

The disease modifying anti-rheumatic drugs (DMARDs) segment to maintain its lead position by 2026

Based on drug class, the disease modifying anti-rheumatic drugs (DMARDs) segment held more than one-third of the total market share of the global anti-rheumatics market in 2018, and is expected to maintain its lead position throughout the forecast period. This is due to its action on the medical conditions rather than acting on the symptoms. However, the nonsteroidal anti-inflammatory drugs (NSAIDs) segment is expected to grow at the fastest CAGR of 3.7% from 2019 to 2026. This is attributed to the rise in incidences of rheumatoid arthritis regarding pain in the joints.

The prescription-based drugs segment to maintain its dominance by 2026

Based on type, the prescription-based drugs segment accounted for the highest share in the global anti-rheumatics market in 2018, contributing for more than three-fourths of the total share, and is estimated to maintain its dominance in terms of revenue throughout the forecast period. This is due to increase in the number of specialized hospitals across the world that provide treatment from specialized medical professionals. However, the over-the-counter drugs segment is estimated to register the highest CAGR of 3.3% from 2019 to 2026, owing to surge in awareness related to treatment options and ease in availability.

North America to lead in terms of revenue during the forecast period

Based on region, North America held the highest share in 2018, accounting for nearly one-third of the global anti-rheumatics market, and will lead during the forecast period. This is due to easy availability of anti-rheumatics and increase in geriatric population that are susceptible to nephrological disorders. However, Asia-Pacific is estimated to witness the largest growth rate, with a CAGR of 3.7% from 2019 to 2026. This is attributed to increase in healthcare expenditure and surge in awareness of anti-rheumatics.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/6289

Leading market players

Pfizer, Inc.
Johnson & Johnsons
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Celegene Corporations
MedImmune, LLC
Takeda Pharmaceutical Company Ltd.
Biogen Inc.
Celltrion Inc.
Amgen Inc.

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
+ + 1 800-792-5285
email us here
Visit us on social media:
Facebook
X
LinkedIn
YouTube